CN108290890B - 治疗性化合物及合成 - Google Patents

治疗性化合物及合成 Download PDF

Info

Publication number
CN108290890B
CN108290890B CN201680064673.0A CN201680064673A CN108290890B CN 108290890 B CN108290890 B CN 108290890B CN 201680064673 A CN201680064673 A CN 201680064673A CN 108290890 B CN108290890 B CN 108290890B
Authority
CN
China
Prior art keywords
formula
compound
compounds
making
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680064673.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN108290890A (zh
Inventor
B.L.D.德科特
J.C.鲁斯彻尔
M.C.F.蒙尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN108290890A publication Critical patent/CN108290890A/zh
Application granted granted Critical
Publication of CN108290890B publication Critical patent/CN108290890B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/12—Oxygen atoms acylated by aromatic or heteroaromatic carboxylic acids, e.g. cocaine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
CN201680064673.0A 2015-09-04 2016-09-01 治疗性化合物及合成 Expired - Fee Related CN108290890B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562214727P 2015-09-04 2015-09-04
US201562214734P 2015-09-04 2015-09-04
US62/214734 2015-09-04
US62/214727 2015-09-04
PCT/US2016/049885 WO2017040772A1 (en) 2015-09-04 2016-09-01 Therapeutic compounds and synthesis

Publications (2)

Publication Number Publication Date
CN108290890A CN108290890A (zh) 2018-07-17
CN108290890B true CN108290890B (zh) 2021-08-06

Family

ID=58188341

Family Applications (5)

Application Number Title Priority Date Filing Date
CN201680064801.1A Expired - Fee Related CN108495854B (zh) 2015-09-04 2016-09-01 用于疼痛的治疗性化合物及其合成
CN201680064673.0A Expired - Fee Related CN108290890B (zh) 2015-09-04 2016-09-01 治疗性化合物及合成
CN201680064790.7A Expired - Fee Related CN108349934B (zh) 2015-09-04 2016-09-01 用于疼痛的治疗性化合物及其合成
CN201680064788.XA Expired - Fee Related CN109153679B (zh) 2015-09-04 2016-09-01 用于疼痛的治疗性化合物及其合成
CN201680064789.4A Expired - Fee Related CN109071540B (zh) 2015-09-04 2016-09-01 用于疼痛的治疗性化合物及其合成

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201680064801.1A Expired - Fee Related CN108495854B (zh) 2015-09-04 2016-09-01 用于疼痛的治疗性化合物及其合成

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201680064790.7A Expired - Fee Related CN108349934B (zh) 2015-09-04 2016-09-01 用于疼痛的治疗性化合物及其合成
CN201680064788.XA Expired - Fee Related CN109153679B (zh) 2015-09-04 2016-09-01 用于疼痛的治疗性化合物及其合成
CN201680064789.4A Expired - Fee Related CN109071540B (zh) 2015-09-04 2016-09-01 用于疼痛的治疗性化合物及其合成

Country Status (11)

Country Link
US (9) US9994572B2 (enExample)
EP (5) EP3344629A4 (enExample)
JP (5) JP6868008B2 (enExample)
CN (5) CN108495854B (enExample)
CA (5) CA2997501C (enExample)
DK (4) DK3344626T5 (enExample)
ES (4) ES2812233T3 (enExample)
IL (5) IL257737B2 (enExample)
MA (1) MA45011A (enExample)
TW (11) TWI641608B (enExample)
WO (5) WO2017040778A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9994572B2 (en) 2015-09-04 2018-06-12 Janssen Pharmaceutica Nv Therapeutic compounds for pain and synthesis thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1058405A (zh) * 1990-07-23 1992-02-05 美国辉瑞有限公司 奎宁环衍生物
WO2008060767A2 (en) * 2006-10-02 2008-05-22 Abbott Laboratories Macrocyclic benzofused pyrimidine derivatives
CN101248073A (zh) * 2005-08-22 2008-08-20 塔加西普特公司 杂芳基-取代的二氮杂三环烷类、其制备方法及其应用
WO2008112734A1 (en) * 2007-03-13 2008-09-18 Targacept, Inc. Heterocyclic-carbonyl-diazabicycloalkanes as modulators of the neuronal nicotinic acetylcholine alpha 4 beta 2, subtype receptor for the treatment of cns related disorders
CN102579458A (zh) * 2012-03-08 2012-07-18 冀中能源峰峰集团有限公司总医院 缓解静点药物所致疼痛和防治静脉炎的药品配方

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1469781A (en) * 1974-06-10 1977-04-06 Boehringer Sohn Ingelheim Production of scopine
US4232026A (en) * 1978-07-20 1980-11-04 Merck & Co., Inc. Diazaditwistanes, and pharmaceutical compositions for treating pain in warm blooded animals containing them
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4532244A (en) * 1984-09-06 1985-07-30 Innes Margaret N Method of treating migraine headaches
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
EP0553264A4 (en) 1990-10-05 1994-07-13 Wayne M Barnes Thermostable dna polymerase
US6432976B1 (en) * 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
DE10050994A1 (de) * 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung
US7358244B2 (en) * 2003-05-28 2008-04-15 Theravance, Inc. Azabicycloalkane compounds
WO2005037832A2 (en) * 2003-10-15 2005-04-28 Targacept, Inc. Azabicycyclic compounds for relieving pain and treating central nervous system disorders
WO2008104955A1 (en) * 2007-02-28 2008-09-04 Ranbaxy Laboratories Limited Azoniatricyclo [3.3.1.0] nonane derivatives as muscarinic receptor antagonists
WO2009124755A1 (en) * 2008-04-08 2009-10-15 European Molecular Biology Laboratory (Embl) Compounds with novel medical uses and method of identifying such compounds
CN101768158B (zh) * 2010-01-04 2013-05-29 南昌弘益科技有限公司 噻托溴铵无水物及其制备方法
JP6102122B2 (ja) * 2012-08-24 2017-03-29 ソニー株式会社 画像処理装置および方法、並びにプログラム
CA2883210C (en) * 2012-09-18 2021-06-15 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic m1 receptor agonists
TW201444849A (zh) * 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TWI627174B (zh) * 2013-03-14 2018-06-21 比利時商健生藥品公司 Ｐ２ｘ７調控劑
KR20160115503A (ko) * 2015-03-27 2016-10-06 차의과학대학교 산학협력단 만성 골수성 백혈병 암 줄기세포의 성장 또는 증식 억제용 조성물 및 이의 스크리닝 방법
GB201505654D0 (en) * 2015-04-01 2015-05-13 Nordic Bioscience As Immunoassay for collagen type VI sequence
GB201505701D0 (en) * 2015-04-02 2015-05-20 Byotrol Plc Anti-microbial composition
US9994572B2 (en) * 2015-09-04 2018-06-12 Janssen Pharmaceutica Nv Therapeutic compounds for pain and synthesis thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1058405A (zh) * 1990-07-23 1992-02-05 美国辉瑞有限公司 奎宁环衍生物
CN101248073A (zh) * 2005-08-22 2008-08-20 塔加西普特公司 杂芳基-取代的二氮杂三环烷类、其制备方法及其应用
WO2008060767A2 (en) * 2006-10-02 2008-05-22 Abbott Laboratories Macrocyclic benzofused pyrimidine derivatives
WO2008112734A1 (en) * 2007-03-13 2008-09-18 Targacept, Inc. Heterocyclic-carbonyl-diazabicycloalkanes as modulators of the neuronal nicotinic acetylcholine alpha 4 beta 2, subtype receptor for the treatment of cns related disorders
CN102579458A (zh) * 2012-03-08 2012-07-18 冀中能源峰峰集团有限公司总医院 缓解静点药物所致疼痛和防治静脉炎的药品配方

Also Published As

Publication number Publication date
CA2997545C (en) 2022-01-11
CN108290890A (zh) 2018-07-17
TW201722951A (zh) 2017-07-01
CN108349934B (zh) 2021-10-22
TW201722954A (zh) 2017-07-01
JP6736661B2 (ja) 2020-08-05
TWI686393B (zh) 2020-03-01
DK3344626T5 (da) 2021-09-06
US10766898B2 (en) 2020-09-08
JP2018527356A (ja) 2018-09-20
ES2812233T3 (es) 2021-03-16
TW201811786A (zh) 2018-04-01
EP3344614B9 (en) 2021-07-28
EP3344614A4 (en) 2019-03-27
US20170066770A1 (en) 2017-03-09
EP3344626A4 (en) 2019-03-27
DK3344626T3 (da) 2020-07-27
CN109153679A (zh) 2019-01-04
CA2997430A1 (en) 2017-03-09
TWI636054B (zh) 2018-09-21
CA2997430C (en) 2021-05-11
TW201920176A (zh) 2019-06-01
TWI639597B (zh) 2018-11-01
TW201819381A (zh) 2018-06-01
EP3344627B1 (en) 2020-07-01
JP2018526387A (ja) 2018-09-13
CA2997501C (en) 2022-05-10
WO2017040770A1 (en) 2017-03-09
US10040797B2 (en) 2018-08-07
US10351566B2 (en) 2019-07-16
EP3344628A4 (en) 2019-03-27
IL257740A (en) 2018-04-30
US20180291024A1 (en) 2018-10-11
ES2808048T9 (es) 2022-02-01
JP6868008B2 (ja) 2021-05-12
CA2997541C (en) 2022-01-11
US10040796B2 (en) 2018-08-07
CA2997543A1 (en) 2017-03-09
US20190112311A1 (en) 2019-04-18
EP3344627A4 (en) 2019-03-27
JP2018531907A (ja) 2018-11-01
TWI713879B (zh) 2020-12-21
EP3344626B9 (en) 2021-08-11
TW201843153A (zh) 2018-12-16
DK3344627T5 (da) 2021-08-30
JP6736660B2 (ja) 2020-08-05
IL257735A (en) 2018-04-30
EP3344614A1 (en) 2018-07-11
US9994572B2 (en) 2018-06-12
CN109071540A (zh) 2018-12-21
JP2018527355A (ja) 2018-09-20
TW201716409A (zh) 2017-05-16
CA2997501A1 (en) 2017-03-09
EP3344626B1 (en) 2020-07-08
EP3344628B1 (en) 2020-07-15
IL257732A (en) 2018-04-30
US10358448B2 (en) 2019-07-23
ES2809703T9 (es) 2022-01-24
TWI663167B (zh) 2019-06-21
CN109153679B (zh) 2022-04-08
WO2017040764A1 (en) 2017-03-09
ES2807901T9 (es) 2022-01-31
CN108495854B (zh) 2021-10-15
TW201833110A (zh) 2018-09-16
US10351565B2 (en) 2019-07-16
IL257737B2 (en) 2023-02-01
US10040795B2 (en) 2018-08-07
TW201835082A (zh) 2018-10-01
IL257732B (en) 2020-11-30
US20180327405A1 (en) 2018-11-15
EP3344629A4 (en) 2019-03-27
DK3344614T5 (da) 2021-08-30
US20170066767A1 (en) 2017-03-09
IL257735B (en) 2022-01-01
ES2808048T3 (es) 2021-02-25
IL257734B (en) 2021-07-29
IL257737B (en) 2022-10-01
US20170066760A1 (en) 2017-03-09
CA2997543C (en) 2022-07-19
TWI695836B (zh) 2020-06-11
WO2017040772A9 (en) 2019-03-07
TW201722955A (zh) 2017-07-01
CN108495854A (zh) 2018-09-04
JP6736659B2 (ja) 2020-08-05
TWI672303B (zh) 2019-09-21
TW201722953A (zh) 2017-07-01
WO2017040767A1 (en) 2017-03-09
ES2807901T3 (es) 2021-02-24
CN109071540B (zh) 2021-06-04
JP2018526388A (ja) 2018-09-13
EP3344628A1 (en) 2018-07-11
DK3344627T3 (da) 2020-07-20
ES2812233T9 (es) 2022-02-18
US20180327406A1 (en) 2018-11-15
TWI707854B (zh) 2020-10-21
IL257734A (en) 2018-04-30
EP3344628B9 (en) 2021-06-30
US10155762B2 (en) 2018-12-18
TWI654188B (zh) 2019-03-21
EP3344627B9 (en) 2021-08-04
DK3344628T5 (da) 2021-07-26
TWI683815B (zh) 2020-02-01
TWI641608B (zh) 2018-11-21
JP6639651B2 (ja) 2020-02-05
EP3344629A1 (en) 2018-07-11
US20170066768A1 (en) 2017-03-09
US20170066769A1 (en) 2017-03-09
CA2997545A1 (en) 2017-03-09
EP3344626A1 (en) 2018-07-11
CA2997541A1 (en) 2017-03-09
MA45011A (fr) 2021-06-02
WO2017040772A1 (en) 2017-03-09
EP3344627A1 (en) 2018-07-11
WO2017040778A1 (en) 2017-03-09
CN108349934A (zh) 2018-07-31
EP3344614B1 (en) 2020-07-08
IL257737A (en) 2018-04-30
DK3344614T3 (da) 2020-07-27
ES2809703T3 (es) 2021-03-05
DK3344628T3 (da) 2020-08-03

Similar Documents

Publication Publication Date Title
CN108290890B (zh) 治疗性化合物及合成

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210806